uniQure Hemophilia B Deal With CSL Leaves M&A Fans Miffed
Dutch Group Gets $450m Upfront For Gene Therapy
Executive Summary
Observers have been expecting uniQure to be sold off as a whole but the Netherlands-based firm has chosen to sell just one asset - EtranaDez - and focus on advancing its Huntington’s disease gene therapy.
You may also be interested in...
Relief For UniQure Hemophilia Program Sends Ball To FTC’s Court
While anticipated, the removal of the hold on uniQure’s hemophilia B program removes significant overhang, as the focus shifts to an anticipated FTC antitrust clearance of its CSL Behring deal.
UniQure Expects To Resolve FDA Clinical Hold Within Three Months
The gene therapy EtranaDez for hemophilia B placed on clinical hold after a patient was diagnosed with liver cancer, but UniQure points to that patient’s extensive history of liver disease.
ASH Data Bring UniQure Closer To Filing Hemophilia B Gene Therapy
The company plans to file with 52-week data for AMT-061 and is confident it won't face the same stringent requirements from the FDA that led to a complete response letter for BioMarin's Roctavian.